

**RGS1 Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP8758a****Specification**

---

**RGS1 Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [Q08116](#)**RGS1 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 5996**Other Names**

Regulator of G-protein signaling 1, RGS1, B-cell activation protein BL34, Early response protein 1R20, RGS1, 1R20, BL34, IER1

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP8758a](/products/AP8758a) was selected from the N-term region of human RGS1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**RGS1 Antibody (N-term) Blocking Peptide - Protein Information****Name** RGS1**Synonyms** 1R20, BL34, IER1**Function**

Regulates G protein-coupled receptor signaling cascades, including signaling downstream of the N-formylpeptide chemoattractant receptors and leukotriene receptors (PubMed: [10480894](http://www.uniprot.org/citations/10480894)). Inhibits B cell chemotaxis toward CXCL12 (By similarity). Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits thereby driving them into their inactive GDP-bound form (PubMed: [10480894](http://www.uniprot.org/citations/10480894), PubMed: [18434541](http://www.uniprot.org/citations/18434541)).

**Cellular Location**

Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cytosol

**Tissue Location**

Detected in peripheral blood monocytes (PubMed:10480894). Expression is relatively low in B-cells and chronic lymphocytic leukemia B-cells; however, in other types of malignant B- cell such as non-Hodgkin lymphoma and hairy cell leukemia, expression is constitutively high (PubMed:8473738).

**RGS1 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**RGS1 Antibody (N-term) Blocking Peptide - Images****RGS1 Antibody (N-term) Blocking Peptide - Background**

RGS1 is a member of the regulator of G-protein signalling family. This protein is located on the cytosolic side of the plasma membrane and contains a conserved, 120 amino acid motif called the RGS domain. The protein attenuates the signalling activity of G-proteins by binding to activated, GTP-bound G alpha subunits and acting as a GTPase activating protein (GAP), increasing the rate of conversion of the GTP to GDP. This hydrolysis allows the G alpha subunits to bind G beta/gamma subunit heterodimers, forming inactive G-protein heterotrimers, thereby terminating the signal.

**RGS1 Antibody (N-term) Blocking Peptide - References**

Bowman,E.P., et.al., J. Biol. Chem. 273 (43), 28040-28048 (1998)